Table 4 Univariate analysis of early death in patients with acute promyelocytic leukaemia

Gender

12.469

0.000

 male

76.2%(16/21)

32.3%(21/65)

 female

23.8%(5/21)

67.7%(44/65)

Occurrence of DS

6.991

0.008

 Yes

38.1%(8/21)

70.3%(45/64)

 No

61.9%(13/21)

29.7%(19/64)

Severity of DS

6.129

0.013

 mild

12.5%(1/8)

66.7%(30/45)

 severe

87.5%(7/8)

33.3%(15/45)

HGB at diagnosis

4.616

0.032

  ≥ 65 g/L

57.1%(12/21)

83.1%(54/65)

  < 65 g/L

42.9%(9/21)

16.9%(11/65)

GFR < 60 ml/min

20%(4/20)

9.8%(6/61)

4.100

0.043

Creatinine > Upper limit^a (mmol/L)

29.4%(5/17)

7.1%(4/56)

0.652

0.419

LDH > 250 U/L

85%(17/20)

61.3%(38/62)

3.849

0.05

WBC count on Day 3 (×10⁹/L)

19.35(1 ~ 249.98)

5.9(0.43 ~ 71.98)

−2.705

0.007

WBC count on Day 3 ≥ 7 × 10⁹/L

27.5%(11/40)

72.5%(29/40)

7.605

0.006

WBC count on Day 3 < 7 × 10⁹/L

3.1%(1/32)

96.9%(31/32)

WBC count on Day 5 (×10⁹/L)

20.54(2.17 ~ 250.32)

10.43(0.24 ~ 112.85)

−2.138

0.033

Cystatin C at diagnosis (mg/L)

1.07(0.81 ~ 2.07)

0.92(0.45 ~ 1.63)

−2.258

0.024

Cystatin C on Day 3 (mg/L)

1.71(0.94 ~ 5.91)

0.97(0.5 ~ 1.53)

−2.318

0.02

Cystatin C on Day 5 (mg/L)

3.33(0.97 ~ 5.09)

1.005(0.6 ~ 1.64)

−2.337

0.019

Cystatin C at chemotherapy (mg/L)

3.245(1.04 ~ 5.55)

0.97(0.7 ~ 2.29)

−2.476

0.013

CRP on Day 5 (mg/L)

119.71(106.08 ~ 133.33)

11.47(1 ~ 104.58)

−2.258

0.024

CRP at chemotherapy (mg/L)

187.71(32.65 ~ 320)

24.06(1.41 ~ 87.82)

−2.378

0.017